-
公开(公告)号：US20240270743A1
公开(公告)日：2024-08-15
申请号：US18682563
申请日：2022-08-09
IPC分类号： C07D471/04 , A61K31/437 , A61K31/444 , A61P3/10 , A61P11/00 , A61P11/06
CPC分类号： C07D471/04 , A61K31/437 , A61K31/444 , A61P3/10 , A61P11/00 , A61P11/06
摘要： Tetrahydropyrazolopyridine-analog compounds of Formula I:
or pharmaceutically acceptable salts or esters thereof, which target the nucleotide-binding oligomerization domain, leucine rich repeat containing X1 (NLRX1) protein are described. Also described are methods of using the compounds in the treatment of chronic and/or inflammatory respiratory diseases, chronic and/or inflammatory diseases of the central nervous system, allergic diseases, autoimmune diseases, cardiovascular diseases, diabetes, hypereosinophilic syndrome, granulomatous disorders, cancer, and/or infectious diseases, among others. Exemplary conditions include asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, Alzheimer's disease, atopic dermatitis, eosinophilic gastroenteritis, eosinophilic esophagitis, diabetes, and granulomatous disorders such as Churg-Strauss syndrome, berylliosis, and sarcoidosis.-
公开(公告)号：US11377437B2
公开(公告)日：2022-07-05
申请号：US17391455
申请日：2021-08-02
IPC分类号： C07D401/04 , C07D401/14 , C07D403/04 , C07D413/04 , C07D413/14
摘要： Provided are compounds that target the lanthionine synthetase C-like protein 2 pathway. The compounds can be used to treat a number of conditions, including autoimmune diseases, inflammatory diseases, chronic inflammatory diseases, diabetes, and infectious diseases, such as lupus, Sjögren's syndrome, rheumatoid arthritis, type 1 diabetes, inflammatory bowel disease, viral diseases, and nonalcoholic steatohepatitis. The compounds can also be used to generate cells, such as immune cells, for treating the conditions.
-
公开(公告)号：US20220017488A1
公开(公告)日：2022-01-20
申请号：US17488984
申请日：2021-09-29
IPC分类号： C07D401/12 , A61P37/00 , A61P19/02 , A61P35/04 , C07D405/12
摘要： Provided are compounds that target plexin domain containing 2 (PLXDC2). The compounds can be used to treat conditions such as inflammatory or immune-mediated diseases, diabetes, infectious diseases, and cancers. The compounds can be used to treat such specific conditions as systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, autoimmune encephalitis, diabetic nephropathy, diabetic retinopathy, psoriasis, and inflammatory bowel disease, among other conditions.
-
公开(公告)号：US11117881B2
公开(公告)日：2021-09-14
申请号：US17127119
申请日：2020-12-18
IPC分类号： C07D401/04 , C07D413/04 , C07D413/14 , C07D401/14 , C07D403/04
摘要： Provided are compounds that target the lanthionine synthetase C-like protein 2 pathway. The compounds can be used to treat a number of conditions, including autoimmune diseases, inflammatory diseases, chronic inflammatory diseases, diabetes, and infectious diseases, such as lupus, Sjögren's syndrome, rheumatoid arthritis, type 1 diabetes, inflammatory bowel disease, viral diseases, and nonalcoholic steatohepatitis. The compounds can also be used to generate cells, such as immune cells, for treating the conditions.
-
公开(公告)号：US20230167083A1
公开(公告)日：2023-06-01
申请号：US17892463
申请日：2022-08-22
IPC分类号： C07D401/14 , A61P17/06 , A61P1/16 , A61P37/06 , A61P3/04 , A61P19/02 , A61P3/10 , A61P1/00 , C07D413/14
CPC分类号： C07D401/14 , A61P17/06 , A61P1/16 , A61P37/06 , A61P3/04 , A61P19/02 , A61P3/10 , A61P1/00 , C07D413/14
摘要： Provided are compounds that target the lanthionine synthetase C-like (LANCL) family of proteins, including LANCL2 and LANCL3. The compounds can be used to treat conditions such as inflammatory diseases, metabolic diseases, autoimmune diseases, cancers, and infectious diseases. Exemplary conditions include inflammatory conditions of the liver, such as nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and cirrhosis; inflammatory conditions of the bile duct, such as primary biliary cholangitis, primary sclerosing cholangitis; inflammatory bowel disease, such as Crohn's disease and ulcerative colitis; lupus, such as systemic lupus erythematosus, lupus nephritis, and cutaneous lupus; arthritis, such as rheumatoid arthritis; hyperglycemia, such as type 1 diabetes, type 2 diabetes, and prediabetes and associated conditions such as atherosclerosis and diabetic kidney disease; psoriasis; and multiple sclerosis.
-
公开(公告)号：US11571419B2
公开(公告)日：2023-02-07
申请号：US17075199
申请日：2020-10-20
发明人： Josep Bassaganya-Riera , Adria Carbo Barrios , Richard Gandour , Julian D. Cooper , Raquel Hontecillas
IPC分类号： A61K31/496 , A61K31/4184 , A61K31/423 , A61K31/4439 , C07D403/12 , C07D403/14 , C07D401/14 , C07D413/12 , C07D413/14 , C07D307/60 , C07D307/68 , C07D213/79 , C07D213/69 , C07C65/40
摘要： Provided are compounds that target the lanthionine synthetase C-like protein 2 pathway. The compounds can be used to treat a number of conditions, including infectious disease, autoimmune disease, diabetes, and a chronic inflammatory disease.
-
公开(公告)号：US20220127250A1
公开(公告)日：2022-04-28
申请号：US17506453
申请日：2021-10-20
摘要： Provided are compounds that target the lanthionine synthetase C-like (LANCL) family of proteins, including LANCL2 and LANCL3. The compounds can be used to treat conditions such as inflammatory diseases, metabolic diseases, autoimmune diseases, cancers, and infectious diseases. Exemplary conditions include inflammatory conditions of the liver, such as nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and cirrhosis; inflammatory conditions of the bile duct, such as primary biliary cholangitis, primary sclerosing cholangitis; inflammatory bowel disease, such as Crohn's disease and ulcerative colitis; lupus, such as systemic lupus erythematosus, lupus nephritis, and cutaneous lupus; arthritis, such as rheumatoid arthritis; hyperglycemia, such as type 1 diabetes, type 2 diabetes, and prediabetes and associated conditions such as atherosclerosis and diabetic kidney disease; psoriasis; and multiple sclerosis.
-
公开(公告)号：US20210355101A1
公开(公告)日：2021-11-18
申请号：US17391455
申请日：2021-08-02
IPC分类号： C07D401/04 , C07D401/14 , C07D403/04 , C07D413/04 , C07D413/14
摘要： Provided are compounds that target the lanthionine synthetase C-like protein 2 pathway. The compounds can be used to treat a number of conditions, including autoimmune diseases, inflammatory diseases, chronic inflammatory diseases, diabetes, and infectious diseases, such as lupus, Sjögren's syndrome, rheumatoid arthritis, type 1 diabetes, inflammatory bowel disease, viral diseases, and nonalcoholic steatohepatitis. The compounds can also be used to generate cells, such as immune cells, for treating the conditions.
-
公开(公告)号：US10028950B2
公开(公告)日：2018-07-24
申请号：US15795906
申请日：2017-10-27
发明人： Josep Bassaganya-Riera , Adria Carbo Barrios , Richard Gandour , Julian D. Cooper , Raquel Hontecillas
IPC分类号： A61K31/496 , A61K31/4184 , A61K31/4439 , A61K31/423 , C07D401/14 , C07D403/12 , C07D403/14 , C07D413/14
摘要： Provided are compounds that target the lanthionine synthetase C-like protein 2 pathway. The compounds can be used to treat a number of conditions, including infectious disease, autoimmune disease, diabetes, and a chronic inflammatory disease.
-
公开(公告)号：US20180055841A1
公开(公告)日：2018-03-01
申请号：US15795906
申请日：2017-10-27
发明人： Josep Bassaganya-Riera , Adria Carbo Barrios , Richard Gandour , Julian D. Cooper , Raquel Hontecillas
IPC分类号： A61K31/496 , A61K31/4439 , A61K31/4184 , A61K31/423
CPC分类号： A61K31/496 , A61K31/4184 , A61K31/423 , A61K31/4439 , C07C65/40 , C07D213/69 , C07D213/79 , C07D307/60 , C07D307/68 , C07D401/14 , C07D403/12 , C07D403/14 , C07D413/12 , C07D413/14
摘要： Provided are compounds that target the lanthionine synthetase C-like protein 2 pathway. The compounds can be used to treat a number of conditions, including infectious disease, autoimmune disease, diabetes, and a chronic inflammatory disease.
-
-
-
-
-
-
-
-
-
搜索结果
43 条记录 (耗时 0.027 秒)
